Rifampicin resistance in pulmonary and extra pulmonary tuberculosis cases in of children

---

Original Article

Author Details : Nidhi Pal*, Kushal Singh, Utkarsh Singh Tomar, Ajay Kumar Sahni

Volume : 11, Issue : 2, Year : 2024

Article Page : 88-91

https://doi.org/10.18231/j.ijmr.2024.016

Suggest article by email

Get Permission

---

Abstract

Background: The prevalence of Rifampicin-resistant MTB/EPTB in children in India is a growing concern. Globally a large proportion of childhood tuberculosis (TB) cases are diagnosed based only on clinical findings. This study was undertaken to measure MTB positivity and their rifampicin resistance rates in different clinical samples from children.
Materials and Methods: Different samples of clinically suspected tuberculosis in children were included. All the samples were tested for Tuberculosis positivity and Rifampicin (Rif) resistance by GeneXpert assay.
Results: A total of 1420 samples were received from presumptive TB patients of all age group from February 2023 to January 2024. Total 1420 samples were analyzed for this study, of which 30% were male and 70% were females. Respiratory samples and extra-pulmonary samples were 1261 (88.8%) and 159 (11.2%) respectively. Among 1420, 211(14.86%) samples were from children and among these 75 (35.55%) were found MTB positive and 7 (9.33%) were Rif resistant MTB. Of 75 MTB detected patients, 77.8% and 22.2% MTB detected in female and male children respectively.
Conclusion: There are higher prevalence of Rif resistant MTB in children so it is important for healthcare providers in India to be vigilant in timely diagnosis, individualized treatment and enhance surveillance. It is essential to combat this growing threat and protect the health of children.
 

Keywords: MTB, Rifampicin, GeneXpert.

How to cite : Pal N, Singh K, Tomar U S, Sahni A K, Rifampicin resistance in pulmonary and extra pulmonary tuberculosis cases in of children. Indian J Microbiol Res 2024;11(2):88-91

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.